US FDA v. COVID Mutants: Multi-Factorial Assessments Will Determine When Product EUAs Need To Change

 
• By Sarah Karlin-Smith

Acting Commissioner Janet Woodcock offers hints as to the content of upcoming guidance on how emerging virus variants may impact vaccine and therapeutic development. US may need multivalent vaccine and multiple boosters. 

COVID gears (shutterstock)
FDA is conducting wide-ranging scenario planning to deal with virus changes • Source: Shutterstock

More from Vaccines

More from Pink Sheet